Cancer Chemotherapeutic Agents as Occupational Hazards: A Literature Review

References

• Falck K, Grohn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1250–1251
   PubMed Web of Science ®Google Scholar
• de Werk N A, Wadden R A, Chiou W L. Exposure of hospital workers to airborne antineoplastic agents. Am J Hosp Pharm 1983; 40: 597–601
   PubMedGoogle Scholar
• Hirst M, Tse S, Mills D G, et al. Occupational exposure to cyclophosphamide. Lancet 1984; 186–188
   PubMed Web of Science ®Google Scholar
• Stellman J M, Aufiero B, Taub R N. Assessment of potential exposure to antineoplastic agents in the health care setting. Prev Med 1984; 13: 245–255
   PubMed Web of Science ®Google Scholar
• Hoffman D. The handling of antineoplastic drugs in a major cancer center. Hosp Pharm 1980; 15(6)302–304
   PubMedGoogle Scholar
• Stolar M, Power L A. Safe handling of cytotoxic drugs in hospitals. QRB July, 1984; 209–213
   PubMedGoogle Scholar
• Anderson R W, Puckett W, Dans W, et al. Risk of handling injectable antineoplastic agents. Am J Hosp Pharm 1982; 39: 1881–1886
   PubMedGoogle Scholar
• Gross J, Johnson B L, Bertino J. Possible hazards of working with cytotoxic agents: A review of the literature. One Nursing Forum 1981; 8(4)10–12
   PubMedGoogle Scholar
• Jones R B, Frank R, Mass T. Safe handling of chemotherapeutic agents: A report from the Mount Sinai Medical Center. Ca Cancer J Clinicians 1984; 33(5)258–263
   Web of Science ®Google Scholar
• Knowles R S, Virden J E. Handling of injectable antineoplastic agents. Br Med J 1980; 281: 589–591
   PubMed Web of Science ®Google Scholar
• Mattia M, Blake S L. Hospital hazards: Cancer drugs. Am J Nursing May, 1983; 758–62
   Web of Science ®Google Scholar
• Stringer B. Use cancer drugs with care. BCNU Rep January-February, 1983; 6–7
   Google Scholar
• Wilson J P, Solimando D. Antineoplastics: A safety hazard?. Am J Hosp Pharm 1981; 38: 624
   PubMedGoogle Scholar
• Ratcliffe J M. Occupational exposure to cancer chemotherapeutic agents in pharmacists and nurses. NIOSH (Industry-wide study EP:80-41). General Printing Office, Washington, DC 1983
   Google Scholar
• American Society of Hospital Pharmacists. ASHP Technical Assistance Bulletin: Handling Cytotoxic Drugs in Hospitals. Professional Services Division, 4630 Montgomery Avenue, Bethesda MD, 20814
   Google Scholar
• Hamilton C, Avis K. Selection criteria for biological safety cabinets for chemotherapy preparation. Am J Hosp Pharm 1982; 39: 968
   PubMedGoogle Scholar
• Harrison B R. Developing guidelines for working with antineoplastic drugs. Am J Hosp Pharm 1981; 38: 1685–1695
   Google Scholar
• National Institutes of Health, Division of Safety. Recommendations for the Safe Handling of Parenteral Antineoplastic Drugs. General Printing Office, Washington, DC 1982
   Google Scholar
• Scott S A, Schrott D, Loesch G. Pharmacy program for improved handling of antineoplastic agents. Am J Hosp Pharm 1983; 40: 1179–82
   PubMedGoogle Scholar
• Society of Hospital Pharmacists of Australia's Specialty Practice Committee on Parenteral Services. Guidelines for safe handling of cytotoxic drugs in pharmacy departments and hospital wards. Hospital Pharm 1981; 16: 17–20
   PubMedGoogle Scholar
• Thestrup-Pedersen K, Christiansen J V, Zachariae H. Precautions for personnel applying topical nitrogen mustard to patients with mycosis fungoides. Dermatologica 1982; 165: 108–113
   PubMedGoogle Scholar
• University of Texas. MD Anderson Hospital and Tumor Institute: Department of Pharmacy Guidelines for Handling Antineoplastic Agents. Texas, Houston 1982, revised
   Google Scholar
• Women's Occupational Health Resource News 5(2). Handling Chemotherapeutic Drugs. Columbia University, New York 1984
   Google Scholar
• Zimmerman P F, Larsen R, Barkley E W, et al. Recommendations for the safe handling of injectable antineoplastic drug products. Am J Hosp Pharm 1981; 38: 1693–1695
   PubMedGoogle Scholar
• Staiano N, Gallelli J F, Adamson R H, et al. Lack of mutagenic activity in urine from hospital pharmacists admixing anti-tumour drugs. Lancet 1981; i: 615–616
   Google Scholar
• Carter S K, Bakowski M T, Hellmann K. Chemotherapy of Cancer (2nd Ed). Wiley and Sons, New York 1981
   Google Scholar
• Crudi C BA. Compounding dilemma: I've kept the drug sterile but have I contaminated myself?. Nat Intraven Ther Assoc 1980; 3: 77
   Google Scholar
• Ladik C, Stoehr G, Maurer M A. Precautionary measures in the preparation of antineoplastics. Am J Hosp Pharm 1980; 37: 1184–1185
   PubMedGoogle Scholar
• Reynolds R D, Ignoffo R, Lawrence J, et al. Adverse reactions to AMSA in medical personnel. Cancer Treat Rpts 1982; 66: 1885
   PubMedGoogle Scholar
• Sotaniemi E A, Sutinen S, Arranto A J, et al. Liver damage in nurses handling cytostatic agents. Acta Med Scand 1983; 214: 181–189
   PubMed Web of Science ®Google Scholar
• Jagun O, Ryan M, Waldron H A. Urinary thioether excretion in nurses handling cytotoxic drugs. Lancet 1982; ii: 443–444
   Google Scholar
• Sorsa M, Falck K, Norppa H, et al. Monitoring genotoxicity in the occupational environment. Scand J Work Environ Health 1981; 7(suppl 4)61–65
   PubMedGoogle Scholar
• Bloom A D. Guidelines for studies of human populations exposed to mutagenic and reproductive hazards. March of Dimes Birth Defects Foundation, White Plains, NY 1981
   Google Scholar
• Gibson J F, Baxter P J, Hedworth W, et al. Urinary mutagenicity assays: A problem arising from the presence of histidine associated growth factors in XAD-2 prepared urine concentrates, with particular relevance to assays carried out using the bacterial fluctuation test. Carcinogenesis 1983; 4: 1471–1476
   PubMed Web of Science ®Google Scholar
• Venitt S, Crofton-Sleigh C, Hunt J, et al. Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: Urinary mutation assays and platinum as markers of absorption. Lancet 1984; ii: 74–77
   Google Scholar
• Zoloth S R, Mikol Y, unpublished results
   Google Scholar
• Nguyen T, Theiss J, Matney T. Exposure of pharmacy personnel to mutagenic antineoplastic drugs. Cancer Res 1982; 42: 4792–4796
   PubMed Web of Science ®Google Scholar
• Norppa H, Sorsa M, Vainio H, et al. Increased sister chromatid exchange frequencies in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1980; 6: 229–301
   Google Scholar
• Waksvik H., Klepp O, Brogger A. Chromosome analyses of nurses handling cytostatic agents. Cancer Treat Rpts 1981; 65(7–8)607–610
   PubMedGoogle Scholar
• Nikula E, Kivinitty K, Leisti J, et al. Chromosome aberrations in lymphocytes of nurses handling cytostatic drugs. Scand J Work Environ Health 1984; 10: 71–74
   PubMed Web of Science ®Google Scholar
• Donner L. Possible risk of working with antineoplastic drugs in horizontal laminar flow hoods. Am J Hosp Pharm 1978; 35: 900
   PubMedGoogle Scholar
• Hoy R H, Stump L. Effect of an air-venting filter device on aerosol production from vials. Am J Hosp Pharm 1984; 41: 324–326
   PubMedGoogle Scholar
• Kleinberg M L, Quinn M J. Airborne drug levels in a laminar flow hood. Am J Hosp Pharm 1981; 38: 1301–1303
   PubMedGoogle Scholar
• Connor H, Laidlaw J, Theiss J, et al. Permeability of latex and polyvinyl chloride gloves to carmustine. Am J Hosp Pharm 1984; 41: 676–679
   PubMedGoogle Scholar
• Laidlaw J L, Connor T H, Theiss J C, et al. Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic agents. Am J Hosp Pharm 1984; 41: 2618–2623
   PubMedGoogle Scholar
• Vaccari P, Tonat K, DeChristoforo R, et al. Disposal of antineoplastic wastes at the National Institutes of Health. Am J Hosp Pharm 1984; 41: 87–92
   PubMedGoogle Scholar
• Pak K, Iwasaki T, Myakawa M, et al. Mutagenic activity of anticancer drugs and the urine of rats given these drugs. Urol Res 1979; 7: 119–124
   PubMed Web of Science ®Google Scholar
• Benedict W, Baker M, Haroun C, et al. Mutagenicity of cancer chemotherapeutic agents in the Salmonella microsome test. Can Res 1977; 37: 2209–2213
   PubMed Web of Science ®Google Scholar
• Seino Y, Nagao M, Yahagi T, et al. Mutagenicity of several classes of antitumor agents to Salmonella Typhimurium TA98, TA100 and TA92. Cancer Res 1978; 38: 2148–2156
   PubMed Web of Science ®Google Scholar
• U.S. Public Health Service. Survey of Compounds Which Have Been Tested for Carcinogenic Activity. General Printing Office, Washington, DC 1979, Publ. No. 149 and Supplements
   Google Scholar
• International Agency for Research on Cancer. Chemicals and industrial Processes Associated with Cancer in Humans. IARC, Lyon 1979, IARC Monograph Suppl 1
   Google Scholar
• Topham J. Do induced sperm-head abnormalities in mice specifically identify mammalian mutagens rather than carcinogens?. Mutat Res 1980; 74: 379–387
   PubMed Web of Science ®Google Scholar
• Seiber S, Adamson R. Toxicity of antineoplastic agents in man: Chromosomal aberrations, antifertility effects, congenital malformations and carcinogenic potential. Adv Cancer Res 1975; 22: 57–155
   PubMedGoogle Scholar
• Shephard T. Catalog of Teratogenic Agents (3rd ed.). Johns Hopkins University Press, Baltimore 1980
   Google Scholar
• Wilson J P, Solimando D. Antineoplastics: A safety hazard?. Am J Hosp Pharm 1981; 38: 624
   PubMedGoogle Scholar
• Bos R P, Leenars A O, Theusu J LG, et al. Mutagenicity of urine from nurses handling cytotoxic drugs: Influence of smoking. Int Arch Occup Environ Health 1983; 50: 359–369
   Web of Science ®Google Scholar